• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 4. Aggregation dynamics, structure, and mechanical properties of bigels
  L. Di Michele,D. Fiocco,F. Varrato,E. Eiser,G. Foffi Soft Matter, 2014,10, 3633-3648
• 5. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Application of L-Lysine, ethyl ester (CAS: 4117-33-3) in Chemical Biology and Pharmaceutical Research

L-Lysine, ethyl ester (CAS: 4117-33-3), a derivative of the essential amino acid L-lysine, has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a crucial building block in peptide synthesis, drug delivery systems, and bio-conjugation strategies. Recent studies have explored its potential in enhancing drug solubility, improving bioavailability, and facilitating targeted drug delivery, making it a valuable tool in modern therapeutic development.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of L-Lysine, ethyl ester in improving the solubility of poorly water-soluble drugs. Researchers utilized this compound to modify the surface properties of drug nanoparticles, resulting in a 40% increase in dissolution rates compared to unmodified counterparts. The study highlighted the compound's role in optimizing drug formulations for oral administration, particularly for hydrophobic active pharmaceutical ingredients (APIs).

In the field of targeted drug delivery, a breakthrough was reported in Advanced Drug Delivery Reviews (2024), where L-Lysine, ethyl ester was incorporated into pH-responsive polymeric carriers. These carriers demonstrated remarkable tumor-targeting capabilities in preclinical models, with the ethyl ester group playing a critical role in maintaining stability during circulation while allowing for controlled release in the acidic tumor microenvironment. The research team observed a 3-fold increase in tumor accumulation compared to conventional delivery systems.

Recent advancements in bioconjugation techniques have also leveraged the unique properties of L-Lysine, ethyl ester. A Nature Biotechnology publication (2023) described its use in creating stable antibody-drug conjugates (ADCs) with improved homogeneity and reduced aggregation. The ethyl ester moiety provided an optimal balance between stability during circulation and efficient intracellular drug release, addressing a long-standing challenge in ADC development.

Ongoing clinical trials (as of Q2 2024) are investigating L-Lysine, ethyl ester-modified formulations for various therapeutic areas, including oncology and infectious diseases. Preliminary results from a Phase I/II trial of a modified antiviral agent showed enhanced pharmacokinetic profiles and reduced side effects, suggesting promising clinical potential for this chemical modification strategy.

The safety profile of L-Lysine, ethyl ester continues to be validated through extensive toxicological studies. Recent data from regulatory submissions indicate excellent biocompatibility at therapeutic doses, with no significant adverse effects observed in comprehensive preclinical safety assessments. This favorable safety profile supports its increasing adoption in pharmaceutical formulations.

Future research directions highlighted in recent literature include exploring the compound's potential in mRNA delivery systems and its application in creating next-generation biomaterials. The unique chemical properties of L-Lysine, ethyl ester, particularly its balance between hydrophilicity and lipophilicity, position it as a versatile tool for addressing current challenges in drug development and delivery.

• 1499-55-4(H-Glu(OMe)-OH)
• 112471-82-6((2s)-2-Azaniumyl-5-cyclohexyloxy-5-oxopentanoate)
• 14487-45-7(DL-Glutamic Acid 5-Methyl Ester)
• 25456-76-2(H-D-Glu-OtBu)
• 16450-41-2(L-Glutamic acid,1,5-diethyl ester)
• 1119-33-1(H-Glu(OEt)-OH)
• 6384-08-3(L-Glutamic Acid 1-Methyl Ester)
• 15911-75-8(tert-butyl (2S)-2-aminopentanoate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)